

PRODUCT INFORMATION

Anti-Daratumumab antibody

Anti-Daratumumab is a chimeric rabbit/human anti-idiotypic antibody designed to specifically target the human therapeutic antibody Daratumumab.

Article number	M9261
Product group	Recombinant Antibody
Technique	ELISA

AntiBodyChain
www.antibodychain.com
order.handling@antibodychain.com
+31(0) 43 2010 660
Wim Duisenbergplantsoen 31
6221SE
Maastricht

Technical information sheet

Plesmanlaan 125
1066 CX Amsterdam
P.O. Box 9190
1006 AD Amsterdam
The Netherlands

Anti-Daratumumab antibody M9261

For research use only

Application

Anti-Daratumumab, is a chimeric rabbit/human anti-idiotypic antibody that specifically targets the human therapeutic antibody Daratumumab. The antibody consists of rabbit variable domains and human constant domains. The recombinant antibody binds mainly to free Daratumumab in samples.

Daratumumab is a human IgG1/kappa antibody, recognising the CD38 molecules.^(1,2) CD38 is expressed in various human tissues, the highest expression is found in hematopoietic tissues with high expression on plasma cells.

Anti-Daratumumab antibody has been evaluated in ELISA, other techniques need to be validated by the user. It is recommended to test anti-Daratumumab by titration of the product in the used technique, using appropriate negative/positive controls.




Figure 1: Titration of Daratumumab to create a pharmacokinetic (PK) curve in bridging ELISA. Anti-Daratumumab antibody was used as capture (0.25 µg/ml) and detection antibody (0.125 µg/ml) in sandwich assay format.⁽⁴⁾ DRT= Daratumumab

References

- 1 Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity. *Front Immunol.* 2020; **11**. PMID:33329591.
- 2 European Medicines Agency (EMA). Darzalex (daratumumab). <https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex>. 2020..
- 3 Großrichter-Wagener C, Kos D, van Leeuwen A, Dijk L, Jeremiasse J, Loeff FC et al. Biased anti-idiotypic response in rabbits leads to high-affinity monoclonal antibodies to biologics. *MAbs* 2020; **12**. PMID:32887534.